<DOC>
	<DOC>NCT01674010</DOC>
	<brief_summary>The primary purpose of this study is to determine whether ELND005 is effective in the maintenance treatment of bipolar 1 disorder when added to other therapies.</brief_summary>
	<brief_title>Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Lamotrigine</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>Meets the DSMIVTR criteria for BPD I by the SCID, prior to the Screening Visit. Has a history in the last 3 years of ≥ 1 manic or mixed episodes of sufficient severity that required hospitalization and/or treatment with a mood stabilizer or antipsychotic, or confirmed by a family member or medical records to ensure the episode fulfills the DSMIVTR criteria. Has experienced a mood episode of any polarity within 4 months prior to the Screening Visit and responded to StOC therapy. Is euthymic at the Screening Visit (ie, score of ≤ 12 on the MADRS and a score of ≤ 12 on the YMRS). Is receiving maintenance treatment for his or her BPD I with either LTG or VPA; on stable doses for past 4 weeks and therapeutic drug levels (total VPA 50125 µg/mL and LTG 1050 µmol/L or as deemed appropriate by the investigator). Dose adjustments made for tolerability reasons will be acceptable. A study patient must meet the following additional criteria to be eligible for randomization in the Doubleblind Randomization Phase of this study: Maintained in a stable euthymic state during Phase 1, defined as YMRS and MADRS scores of ≤ 12, with the following exceptions: a maximum of 2 nonconsecutive excursions will be allowed throughout Phase 1. Excursions are defined as YMRS or MADRS scores &gt;12 but ≤ 16. Woman of childbearing potential who is unwilling or unable to use an acceptable method of birth control or is using a prohibited contraceptive method. Is found to be actively suicidal on the CSSRS (answer of "yes" to question 4 or 5 [current or over the last 30 days]) or a score of ≥4 on the MADRS item 10 at the Screening Visit. Has suboptimally treated thyroid disease as evidenced by thyroidstimulating hormone (TSH) &gt;3 mIU/L at the Screening Visit. Has received electroconvulsive therapy (ECT) during the current episode or within 6 months prior to the Screening Visit. Has an estimated glomerular filtration rate &lt;40 mL/min/1.73 m2 according to the Modification of Diet in Renal Disease formula. A study patient who meets ANY of the above and ANY of the criteria below will not be eligible for enrollment in the Doubleblind Randomization Phase of this study: Has current signs or symptoms of psychosis. Has become actively suicidal as defined by CSSRS answer of "yes" to question 4 or 5 (current or over the last 30 days) and/or has a score of ≥4 on MADRS item 10.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>